Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.60 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | CHKA | P35790 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26159147 | 0.92 | HDAC1 (0.72) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL19260249 | 0.92 | HDAC1 (0.72) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL30027318 | 0.85 | ACHE (0.57) | HDAC6HDAC1TNFMEN1KMT2A | |
| SCHEMBL700477 | 0.85 | ACHE (0.52) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL23754421 | 0.85 | ACHE (0.57) | HDAC6HDAC1TNFMEN1KMT2A | |
| SCHEMBL20879365 | 0.83 | HDAC1 (0.85) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL15524900 | 0.83 | HDAC1 (0.52) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL15528419 | 0.83 | HDAC1 (0.65) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL26159155 | 0.82 | HDAC1 (0.68) | HDAC6HDAC1TNFMEN1KMT2A | |
| SCHEMBL29126108 | 0.81 | HDAC6 (0.57) | HDAC6HDAC1HDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934255-B2 | Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200039933-A1 | NRF AND HIF ACTIVATORS/HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2020-02-06 | — | — | US | disclosed |
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009004430-A1 | N-BENZYL OXAZOLIDINONES AND RELATED HETEROCYCLEIC COMPOUNDS AS POTENTIATORS OF GLUTAMATE RECEPTORS | PFIZER INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934255-B2 | Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same | HIF1AN, KEAP1, NFE2L2 | HDAC6 35/4885HDAC1 11/4885HDAC3 32/4885 |
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | HDAC6 76/4885HDAC1 405/4885HDAC3 233/4885 |
| US-20200039933-A1 | NRF AND HIF ACTIVATORS/HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | HIF1AN, KEAP1, NFE2L2 | HDAC6 35/4885HDAC1 11/4885HDAC3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.